Lithium, the most established mood stabilizer for bipolar disorder, carries a well-documented risk to the kidneys, and one of its lesser-known urinary complications is retention, the inability to fully empty the bladder. A large analysis of a national adverse drug reaction database found that lithium had a statistically significant association with urinary retention, and the finding was notable partly because retention was not even listed as a known side effect in lithium’s official product labeling. The relationship between lithium and the urinary tract is more layered than most patients and even some clinicians realize, touching everything from water-channel proteins deep inside kidney cells to structural changes in renal tissue that can take years to develop.
Why Lithium Is Still Used Despite Its Kidney Risks
Lithium has been the cornerstone of bipolar disorder treatment for over half a century. It remains the go-to mood stabilizer for acute mania, long-term mood maintenance, and, uniquely among psychiatric medications, suicide prevention. No other agent has matched its track record on that last point, which is a major reason clinicians keep prescribing it despite its well-known side-effect profile.1PubMed. Potential mechanisms of action of lithium in bipolar disorder. Current understanding The drug remains the mainstay of pharmacotherapy for bipolar disorder across multiple phases of illness.2PubMed Central. The role of lithium in the treatment of bipolar disorder: convergent evidence for neurotrophic effects as a unifying hypothesis
That clinical indispensability is exactly what makes lithium’s kidney effects so consequential. If it were easy to swap out for another drug with the same benefits, the renal concerns would be simpler to manage. Instead, clinicians face a genuine balancing act: the mental health risks of stopping lithium are substantial, and the kidney risks of continuing it are real but variable. Understanding how and why lithium causes urinary problems, including the less-discussed issue of retention, helps patients and their doctors navigate that trade-off with clearer eyes.
What Lithium Does to Kidney Water Channels
The kidney’s ability to concentrate urine depends heavily on a water-channel protein called aquaporin-2 (AQP2). Normally, when your body needs to conserve water, a hormone called vasopressin signals the kidney’s collecting duct cells to insert AQP2 channels into their surface, allowing water to be reabsorbed from urine back into the bloodstream. Lithium disrupts this process dramatically. In animal studies, lithium treatment reduced AQP2 expression to roughly a third of normal levels after ten days and to just a few percent after 25 days. At the same time, the animals developed severe polyuria, producing far more urine than normal.3PubMed Central. Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla
The mechanism goes deeper than simply blocking a surface receptor. Lithium reduces AQP2 at the level of gene transcription, meaning the cells make less of the protein in the first place. Research in collecting duct cells has shown that lithium decreases AQP2 protein abundance, messenger RNA levels, and transcription activity. About one in five patients treated with lithium develops a condition called nephrogenic diabetes insipidus (NDI), where the kidneys lose the ability to concentrate urine despite normal hormone signaling.4PubMed. Lithium reduces aquaporin-2 transcription independent of prostaglandins Proteomic studies have confirmed that chronic lithium treatment not only reduces AQP2 but also alters broader kidney function and triggers structural changes in the inner medullary collecting ducts.5PubMed Central. Proteomic analysis of lithium-induced nephrogenic diabetes insipidus: mechanisms for aquaporin 2 down-regulation and cellular proliferation
A key enzyme involved is glycogen synthase kinase-3 (GSK3), which lithium inhibits. That inhibition sets off a cascade: in the short term, it disrupts the vasopressin signaling pathway that tells collecting duct cells to reabsorb water. Over longer periods, it can trigger cell proliferation and even tiny cyst formation in the kidneys, physically altering the ducts and making them less responsive to vasopressin.6PubMed Central. Glycogen synthase kinase-3 regulation of urinary concentrating ability So the damage operates on two timescales: a relatively quick functional change and a slower structural one.
From Polyuria to Retention: An Unexpected Pairing
Most discussions of lithium and the urinary tract focus on polyuria, producing too much dilute urine, because that is the most common kidney-related side effect and the one driven directly by AQP2 loss. Urinary retention, where the bladder cannot empty properly, seems like the opposite problem. Yet both can occur, sometimes even in the same patient.
A nationwide analysis of spontaneous adverse drug reaction reports found that lithium had a statistically significant reporting odds ratio for urinary retention. Of the 39 drugs flagged in that analysis, lithium was one of just five for which retention was not described in their official product labeling, meaning it was essentially a hidden risk.7European Urology Focus. Drug-induced Urinary Retention: An Analysis of a National Spontaneous Adverse Drug Reaction Reporting Database The finding suggests that retention with lithium is underrecognized rather than rare.
How does a drug famous for making the kidneys produce too much urine simultaneously interfere with the bladder’s ability to release it? The answer likely involves lithium’s broad effects on the nervous system. Psychotropic medications, lithium included, can alter genitourinary function by affecting the neurological systems that control bladder muscle contraction, sphincter relaxation, and urinary flow. These effects on continence and voiding can happen independently of what lithium does to the kidney’s water channels.8PubMed Central. Genitourinary and sexual adverse effects of psychotropic medication The result can be a paradoxical situation: the kidneys are flooding the bladder with large volumes of dilute urine, while the bladder’s own emptying reflexes are impaired. That combination can escalate quickly.
When Drug Combinations Make Things Worse
Lithium is rarely the only medication a person with bipolar disorder takes. Many patients are on combination regimens that include antipsychotics, anticonvulsants, or antidepressants, and some of these co-prescribed drugs carry their own anticholinergic effects, which directly impair bladder contraction. A published case report illustrates this clearly: a patient on both lithium and quetiapine (an atypical antipsychotic) developed acute urinary retention alongside polyuria. The proposed explanation was that quetiapine’s anticholinergic properties weakened the bladder’s ability to contract while lithium’s renal effects were simultaneously driving excessive urine production, creating a perfect storm.9Malaysian Journal of Psychiatry. Acute Urinary Retention Associated with Quetiapine
This kind of compounding risk is easy to miss in clinical practice. A psychiatrist tracking lithium levels and mood stability may not be thinking about bladder function. A urologist treating retention may not be thinking about mood stabilizers. The practical takeaway for patients is that any new urinary symptoms, difficulty starting urination, a weak stream, feeling like the bladder is not emptying, or suddenly needing to urinate much more often, deserve prompt attention. Mentioning all your medications to every clinician involved matters more than you might assume.
Structural Kidney Damage Over Time
Beyond the functional disruption to water channels, long-term lithium use can cause physical changes in kidney tissue. Renal biopsies from patients on maintenance lithium therapy have shown chronic focal interstitial nephropathy, a pattern of scarring between the kidney’s tubules. One study found chronic tubulointerstitial nephropathy in every patient biopsied, with cortical and medullary cysts present in roughly two-thirds and tubular dilation in a third.10Journal of the American Society of Nephrology. Lithium Nephrotoxicity: A Progressive Combined Glomerular and Tubulointerstitial Nephropathy Distal tubular dilation was a prominent feature in lithium-treated patients specifically, compared to patients with affective illnesses who had never taken the drug. Researchers also identified a lesion in the renal tubular lining that appeared only in lithium-treated patients.11Recent Advances in Neuropsycho-Pharmacology. Renal Biopsy Studies of Lithium, Pre-Lithium and Donor Kidneys
These structural changes matter for the retention question because damaged, dilated, or cystic tubules do not respond normally to hormonal signals. Once the kidney’s plumbing is physically altered, simply adjusting the lithium dose or even stopping the drug may not fully restore normal urinary function. The kidney, in essence, has been remodeled. That said, the risk of progressive glomerular and tubular damage during lithium maintenance is the exception rather than the rule, and is related more to episodes of lithium toxicity, higher maintenance blood levels, other medications, other illnesses, and age than to the total duration of therapy alone.
Amiloride and the Entry-Point Theory
One of the more promising findings in lithium nephrology is that blocking lithium’s entry into kidney cells can prevent much of the downstream damage. Lithium gets into the principal cells of the collecting duct through the epithelial sodium channel, known as ENaC. Amiloride, a mild diuretic that blocks ENaC, essentially closes the door lithium uses to enter these cells. In both cell cultures and live animal studies, amiloride reduced lithium transport into the cells, lowered intracellular lithium concentrations, and prevented lithium-induced inactivation of GSK3-beta. Animals given lithium alongside amiloride were protected from AQP2 downregulation and polyuria.12PubMed. Amiloride blocks lithium entry through the sodium channel thereby attenuating the resultant nephrogenic diabetes insipidus
Genetic studies have reinforced this picture. Mice engineered to lack functional ENaC in their collecting ducts were protected from lithium-induced NDI entirely, strongly supporting the idea that ENaC-mediated lithium entry is central to how the kidney damage begins.13PubMed Central. alphaENaC-mediated lithium absorption promotes nephrogenic diabetes insipidus For patients, this translates into a practical option: amiloride co-therapy can be discussed with your prescriber as a strategy to protect kidney function while continuing lithium. It does not eliminate all risk, but the rationale is well-supported by animal data and has been used clinically.
Whether amiloride also helps with the retention side of things is less clear. The retention signal appears to involve neurological effects on bladder function that are separate from what happens inside collecting duct cells. Still, reducing the volume of urine the kidney produces by protecting AQP2 channels could indirectly reduce the strain on a bladder that is already struggling to empty. The two problems, overproduction and under-emptying, are mechanistically distinct but clinically intertwined.
Recovery After Stopping Lithium
A common assumption is that lithium’s kidney effects reverse once the drug is stopped. The truth is more complicated. Some recovery does occur, but it is often partial and slow. One study of patients who discontinued long-term lithium therapy found that concentrating capacity improved during the first two months but plateaued after that. A year after stopping lithium, most patients in the study still had concentrating capacity below normal thresholds.14PubMed. Renal concentrating capacity in long-term lithium treatment and after withdrawal of lithium The animal data on AQP2 tells a consistent story: even after lithium was stopped and other interventions (like thirsting or synthetic vasopressin) were tried, AQP2 levels only partially recovered.3PubMed Central. Lithium-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla
In some cases, NDI persists indefinitely. A case report documented a patient whose nephrogenic diabetes insipidus continued 57 months after lithium was discontinued. A review of the literature identified several similar cases of apparently permanent NDI following lithium therapy.15Endocrine Practice. Nephrogenic Diabetes Insipidus Persisting 57 Months after Cessation of Lithium Carbonate Therapy: Report of a Case and Review of the Literature This tracks with the structural changes described earlier. Once the collecting ducts have been physically remodeled with cysts and fibrosis, removing the drug does not undo the remodeling. The kidney is not just functionally impaired; parts of it have been rebuilt in a less functional way.
This is why the decision to continue or discontinue lithium in the face of kidney changes is genuinely difficult. Stopping the drug does not guarantee recovery, and the psychiatric consequences of discontinuation, including relapse and increased suicide risk, are substantial. Current guidelines emphasize that balancing these competing harms requires input from both psychiatry and nephrology, and ideally a shared decision with the patient.16PubMed Central. Lithium and nephrotoxicity: a literature review of approaches to clinical management and risk stratification
Monitoring and Early Detection
Guidelines exist for routine monitoring of lithium blood levels and kidney function, typically including serum creatinine and estimated glomerular filtration rate at regular intervals. The principle is straightforward: using the lowest effective lithium dose, maintaining close surveillance of kidney function and drug levels, and catching nephrotoxicity early are all critical for preventing irreversible injury.17PubMed Central. Diagnosis and Management of Acute and Chronic Lithium-Associated Nephrotoxicity In practice, though, the picture is murkier. It remains unclear exactly when a nephrologist should be brought in, or at what point the kidney risk tips the scales against continuing lithium.16PubMed Central. Lithium and nephrotoxicity: a literature review of approaches to clinical management and risk stratification
For the specific issue of urinary retention, there is even less guidance. Because retention was not listed in lithium’s product labeling until recently (and may still not be in many countries), clinicians may not think to screen for it. Patients who notice they are going to the bathroom frequently but also feeling like they cannot fully empty, or who develop sudden inability to urinate, should flag these symptoms explicitly. In older adults, who may already have age-related bladder changes or prostate enlargement, these symptoms can easily be attributed to aging rather than medication effects. Side effects are among the most frequent reasons patients stop taking their mood stabilizers, and early identification of urinary issues gives clinicians the chance to intervene, whether by adjusting the dose, adding a protective agent like amiloride, or reconsidering the regimen, before a crisis forces the decision.
How Other Mood Stabilizers Compare on Urinary Effects
Lithium is not the only mood stabilizer with urinary side effects, though it is the one with the most direct kidney impact. Sodium valproate, an anticonvulsant used as a mood stabilizer, has been associated with urinary complications including enuresis (bedwetting) and polyuria. In one study of children with epilepsy, the valproate group had a urinary complication rate of about eleven percent, while the carbamazepine group had none.18Innovative Journal of Pediatrics. The Effect of Sodium Valproate on Urinary Frequency and Enuresis Compared to Carbamazepine in Children with Epilepsy That study was in children with epilepsy rather than adults with bipolar disorder, so the numbers do not translate directly, but they illustrate that urinary effects are not unique to lithium among drugs in this class.
The key difference is the mechanism. Valproate’s urinary effects do not involve the same AQP2 downregulation or structural kidney remodeling that lithium causes. They appear to be more transient and less likely to cause permanent damage. Carbamazepine, another anticonvulsant sometimes used in bipolar disorder, had essentially no urinary complications in the same study. For patients whose kidneys are already showing signs of lithium-related changes, these alternatives may be worth discussing, keeping in mind that none of them match lithium’s evidence base for suicide prevention.
Older Adults and Heightened Vulnerability
Age compounds nearly every aspect of lithium’s kidney and urinary risks. Kidney function naturally declines with age, so the same lithium dose produces higher blood levels in an older adult than in a younger one. The structural changes lithium causes in the collecting ducts add to whatever age-related kidney decline is already underway. Bladder function also changes with age: the detrusor muscle weakens, residual urine volume increases, and in men, prostate enlargement can physically obstruct outflow. Layer lithium’s neurological effects on bladder control on top of these baseline changes and the risk of clinically significant retention rises.
The adverse drug reaction database that flagged lithium for urinary retention did not break down its results by age, but the reporting pattern is consistent with what geriatric pharmacology would predict. Older adults are more likely to be on multiple medications with overlapping anticholinergic or urinary effects, less likely to have robust kidney reserve, and more likely to attribute new urinary symptoms to “just getting older” rather than a medication side effect. For clinicians managing lithium in older patients, periodic assessment of post-void residual urine volume, not just serum creatinine, could catch retention before it becomes an emergency.